Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Nab-Paclitaxel in TNBC with Bone Metastasis
NCT06538896Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in triple-negative breast cancer (TNBC), sponsored by Zhejiang Cancer Hospital. Started Aug 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06538896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538896.